Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.540
0.00 (-0.02%)
Jul 26, 2024, 4:30 PM EDT - Market closed
Aligos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 13.79 | 15.53 | 13.91 | 4.36 | - | - | Upgrade
|
| Revenue Growth (YoY) | -1.90% | 11.66% | 219.04% | - | - | - | Upgrade
|
| Cost of Revenue | 71.27 | 73.04 | 85.08 | 104.15 | 79.89 | - | Upgrade
|
| Gross Profit | -57.48 | -57.51 | -71.17 | -99.79 | -79.89 | - | Upgrade
|
| Selling, General & Admin | 28.05 | 29.89 | 26.41 | 28.53 | 17.94 | 10.1 | Upgrade
|
| Research & Development | - | - | - | - | - | 44.04 | Upgrade
|
| Operating Expenses | 28.05 | 29.89 | 26.41 | 28.53 | 17.94 | 54.13 | Upgrade
|
| Operating Income | -85.53 | -87.4 | -97.58 | -128.32 | -97.83 | -54.13 | Upgrade
|
| Interest Expense | - | - | - | - | -0.24 | -0.04 | Upgrade
|
| Interest & Investment Income | 4.13 | 4.3 | 1.52 | 0.24 | 1.26 | 1.6 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.05 | -0.05 | -0.04 | -0.01 | 0.12 | -0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | -16.64 | -3.01 | 0.16 | -0.1 | -11.68 | 0.44 | Upgrade
|
| EBT Excluding Unusual Items | -98.08 | -86.16 | -95.94 | -128.19 | -108.38 | -52.18 | Upgrade
|
| Asset Writedown | -0.72 | -0.72 | - | - | - | - | Upgrade
|
| Pretax Income | -98.81 | -86.88 | -95.94 | -128.19 | -108.38 | -52.18 | Upgrade
|
| Income Tax Expense | 0.78 | 0.8 | 0.11 | 0.14 | 0.16 | 0.09 | Upgrade
|
| Net Income | -99.59 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | Upgrade
|
| Net Income to Common | -99.59 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | Upgrade
|
| Shares Outstanding (Basic) | 93 | 64 | 43 | 40 | 10 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 93 | 64 | 43 | 40 | 10 | 2 | Upgrade
|
| Shares Change (YoY) | 116.31% | 50.51% | 7.13% | 299.03% | 397.62% | 68.42% | Upgrade
|
| EPS (Basic) | -1.08 | -1.36 | -2.25 | -3.22 | -10.87 | -26.04 | Upgrade
|
| EPS (Diluted) | -1.08 | -1.36 | -2.25 | -3.22 | -10.87 | -26.04 | Upgrade
|
| Free Cash Flow | -79.44 | -79.02 | -80.33 | -116.55 | -76.33 | -49.55 | Upgrade
|
| Free Cash Flow Per Share | -0.86 | -1.23 | -1.88 | -2.92 | -7.64 | -24.69 | Upgrade
|
| Operating Margin | -620.15% | -562.84% | -701.66% | -2943.82% | - | - | Upgrade
|
| Free Cash Flow Margin | -575.96% | -508.83% | -577.64% | -2673.87% | - | - | Upgrade
|
| EBITDA | -84.14 | -85.84 | -95.27 | -125.3 | -95.1 | -52.74 | Upgrade
|
| D&A For EBITDA | 1.39 | 1.56 | 2.31 | 3.02 | 2.74 | 1.4 | Upgrade
|
| EBIT | -85.53 | -87.4 | -97.58 | -128.32 | -97.83 | -54.13 | Upgrade
|
Source: S&P Capital IQ. Standard template.